ovarian adenocarcinoma
Showing 1 - 8 of 8
CINSARC Genomic Signature as Predictor of Resectability of
Completed
- Ovarian Adenocarcinoma
- CINSARC signature
-
Toulouse, FranceInstitut Claudius Regaud Institut Universitaire du cancer Toulou
Dec 22, 2022
Ovarian Cancer, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma Trial in Seattle (Exercise Counseling, Aerobic
Terminated
- Ovarian Cancer
- +21 more
- Exercise Counseling
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 6, 2022
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma Trial in Guam, United States (Biospecimen
Recruiting
- Acinar Cell Carcinoma
- +93 more
- Biospecimen Collection
- +2 more
-
Birmingham, Alabama
- +998 more
Aug 23, 2022
Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant Trial in Bethesda, Nashville (TC-510, Fludarabine,
Recruiting
- Mesothelioma
- +14 more
- TC-510
- +2 more
-
Nashville, TennesseeSarah Cannon Research Institute
Jul 14, 2022
Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma Trial in United States (PDR001, LAG525)
Completed
- Small Cell Lung Cancer
- +7 more
- PDR001
- LAG525
-
San Francisco, California
- +19 more
May 4, 2022
YKL-40 in Serum Samples From Newly Diagnosed Stage III-IV
Terminated
- Fallopian Tube Adenocarcinoma
- +29 more
- Cytology Specimen Collection Procedure
- Laboratory Biomarker Analysis
-
Mobile, Alabama
- +130 more
May 21, 2018
Ovarian Adenocarcinoma, Fallopian Tube Adenocarcinoma, Primary Peritoneal Carcinoma Trial in Villejuif (Cisplatin, Bevacizumab)
Completed
- Ovarian Adenocarcinoma
- +2 more
-
Villejuif, Val de Marne, FranceGustave Roussy
Jan 25, 2016